HC Wainwright & Co. Reiterates Buy on ADC Therapeutics, Maintains $12 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns has reiterated a 'Buy' rating on ADC Therapeutics (NYSE:ADCT) and maintained a $12 price target.
July 25, 2023 | 10:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ADC Therapeutics' stock rating has been reiterated as 'Buy' by HC Wainwright & Co. with a maintained price target of $12.
The reiteration of a 'Buy' rating by a reputable analyst firm like HC Wainwright & Co. is a positive signal for investors. The maintained price target of $12 also indicates the firm's confidence in the stock's potential. This could lead to increased investor confidence and potentially a short-term increase in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100